J. Mattern

发表

Clinical relevance of predictive tests for cancer chemotherapy.

M. Volm, J. Mattern, Manfred Volm, 1982, Cancer treatment reviews.

Cellular drug resistance in lung cancer

J. Mattern, 2004 .

Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.

M. Büchler, I. Herr, M. Zöller, 2010, Cancer research.

Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo

I. Herr, P. Krammer, K. Debatin, 2004, International journal of cancer.

Glucocorticoid-mediated apoptosis resistance of solid tumors.

M. Büchler, I. Herr, J. Mattern, 2009, Results and problems in cell differentiation.

Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases

M. Volm, T. Efferth, J. Mattern, 2004, Clinical & Experimental Metastasis.

Hypoxia Induces EMT in Low and Highly Aggressive Pancreatic Tumor Cells but Only Cells with Cancer Stem Cell Characteristics Acquire Pronounced Migratory Potential

M. Büchler, I. Herr, J. Werner, 2012, PloS one.

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma

H. Friess, M. Büchler, A. Apel, 2008, British Journal of Cancer.

Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.

M. Volm, J. Mattern, R. Koomägi, 1996, Anticancer research.

P-glycoprotein expression in treated and untreated human breast cancer.

J. Schneider, M. Volm, T. Efferth, 1989, British Journal of Cancer.

Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors

R. Penzel, I. Herr, N. Gassler, 2006, Cell Death and Differentiation.

Prognostic value of oncoproteins for the survival of patients with nonsmall cell lung carcinomas.

M. Volm, J. Mattern, P. Drings, 1993, International journal of oncology.

Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy

I. Herr, Xi Xiao, P. Schemmer, 2016, Cell Death and Disease.

Role of oxygenation and vascularization in drug resistance

M. Volm, J. Mattern, 1998, Cytotechnology.

Relationship between chemoresistance of lung tumours and cigarette smoking.

M. Volm, J. Mattern, B. Samsel, 1990, British Journal of Cancer.

PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.

M. Volm, J. Mattern, R. Koomägi, 1999, Anticancer research.

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo

H. Dienemann, I. Herr, P. Schnabel, 2005, British Journal of Cancer.

M. Volm, J. Mattern, R. Koomägi, 1998, Carcinogenesis.

Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype.

M. Volm, T. Efferth, J. Mattern, 2002, Anticancer research.

Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer

H. Friess, M. Büchler, A. Apel, 2008, Cancer Gene Therapy.

Immunohistochemical detection of p53 in non-small-cell lung cancer.

M. Volm, J. Mattern, 1994, Journal of the National Cancer Institute.

Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.

M. Volm, T. Efferth, J. Mattern, 1992, Anticancer research.

Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases

M. Volm, G. Kaick, J. Mattern, 1994, Clinical & Experimental Metastasis.

Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas.

M. Volm, J. Mattern, G. Stammler, 1997, European journal of cancer.

DNA distribution in non-small-cell lung carcinomas and its relationship to clinical behavior.

M. Volm, M. Vogt-Schaden, J. Šonka, 1985, Cytometry.

Lung Cancer Protein Expression Profiles of Smokers and Non-Smokers.

M. Volm, T. Efferth, J. Mattern, 2004, Cancer genomics & proteomics.

Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.

M. Volm, J. Mattern, G. Stammler, 1997, British Journal of Cancer.

Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas.

M. Volm, J. Mattern, G. Stammler, 1995, Cancer letters.

Characteristics of long-term survivors of untreated lung cancer.

M. Volm, J. Mattern, R. Koomägi, 2002, Lung cancer.

Role of angiogenesis in drug resistance.

J. Mattern, 2001, Anticancer research.

Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas.

M. Volm, J. Mattern, R. Koomägi, 1995, International journal of oncology.

Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.

M. Volm, T. Efferth, J. Mattern, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects

M. Büchler, I. Herr, T. Wenger, 2007, Cancer Gene Therapy.

M. Volm, J. Mattern, R. Koomägi, 1999, Anticancer research.

Detection of P-glycoprotein in human leukemias using monoclonal antibodies

M. Volm, T. Efferth, J. Mattern, 1989, Blut.

Detection of drug resistance in human ovarian carcinoma

M. Volm, T. Efferth, J. Mattern, 2004, Archives of Gynecology and Obstetrics.

Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein

M. Volm, T. Efferth, J. Mattern, 2004, Journal of Cancer Research and Clinical Oncology.

Detection of the multidrug resistant phenotype in human tumours by monoclonal antibodies and the streptavidin-biotinylated phycoerythrin complex method.

M. Volm, T. Efferth, J. Mattern, 1989, European journal of cancer & clinical oncology.

Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas.

M. Volm, J. Mattern, R. Koomägi, 1999, Anticancer research.

Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy.

H. Friess, A. Kolb, M. Büchler, 2006, Cancer letters.

Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P‐glycoprotein 170, and glutathione S‐transf erase‐π in human lung tumors

M. Volm, J. Mattern, B. Samsel, 1992, Cancer.

Expression of resistance‐related proteins in nephroblastoma after chemotherapy

M. Volm, S. Schneider, J. Mattern, 1995, International journal of cancer.

Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer

H. Friess, A. Kolb, M. Büchler, 2006, BMC Cancer.

Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas.

P. Altevogt, I. Herr, T. Wenger, 2006, International journal of oncology.

Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.

M. Volm, J. Mattern, R. Koomagi, 1998, International journal of oncology.

Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.

M. Volm, T. Efferth, J. Mattern, 1992, Anticancer research.

Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA topoisomerase II in human tumors.

M. Volm, T. Efferth, J. Mattern, 1992, Oncology.

Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.

M. Volm, J. Mattern, G. Stammler, 1997, Anticancer research.

Spontaneous apoptosis in ovarian cancer: an unfavorable prognostic factor.

D. Wallwiener, M. Volm, M. Kaufmann, 1998, International journal of oncology.

Cell Cycle Arrest by Glucocorticoids May Protect Normal Tissue and Solid Tumors from Cancer Therapy

M. Büchler, I. Herr, J. Mattern, 2007, Cancer biology & therapy.

Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo

M. Volm, J. Mattern, E. Pommerenke, 2005, Journal of Cancer Research and Clinical Oncology.

Circumvention of multi‐drug resistance in human kidney and kidney carcinoma in vitro

M. Volm, T. Efferth, J. Mattern, 1991, Cancer.

Flow cytometric analysis of primary lung carcinomas and their lymph node metastases.

M. Volm, M. Vogt-Schaden, J. Mattern, 1987, Anticancer research.

In vivo uptake of 57Co, 54Mn and 65Zn by peripheral lymphocytes, tumor and various organs of rats bearing Walker 256 carcinosarcoma.

J. Mattern, K. Wayss, J. Schuhmacher, 1979, European journal of cancer.

Corticosteriod-induced chemotherapy resistance in urological cancers

I. Herr, M. Hohenfellner, K. Debatin, 2006, Cancer biology & therapy.

TESTING CHEMOSENSITIVITY OF HUMAN TUMOURS

J. Mattern, 1983, The Lancet.

Pathophysiologic basis of contrast enhancement in breast tumors

G Brix, M V Knopp, G van Kaick, 1999, Journal of magnetic resonance imaging : JMRI.

Increased resistance to Doxorubicin in human non-small-cell lung carcinomas with metallothionein expression.

M. Volm, J. Mattern, 1992, International journal of oncology.

Detection of drug resistance and P-glycoprotein in human renal cell carcinomas.

M. Volm, T. Efferth, G. Mickisch, 1990, European urology.

Sensitivity of human non-small cell lung cancer xenografts to cyclophosphamide and cisplatin.

M. Volm, J. Mattern, K. Wayss, 1987, In vivo.

Influence of hormone therapy on human lung tumors transplanted into nude mice.

M. Volm, J. Mattern, B. Runnebaum, 1985, Oncology.

Human tumor xenografts as model for drug testing

M. Volm, E. W. Hahn, J. Mattern, 1988, Cancer and Metastasis Reviews.

Sensitivity tests of tumors to cytostatic agents

M. Volm, M. Kaufmann, J. Mattern, 2004, Zeitschrift für Krebsforschung und Klinische Onkologie.

Studies on the specificity of tissue supernatants on the proliferation of liver in baby-rats.

M. Volm, J. Mattern, K. Wayss, 1980, Experimentelle Pathologie.

Prognostic significance of DNA patterns and resistance‐predictive tests in non‐small cell lung carcinoma

M. Volm, J. Šonka, J. Mattern, 1985, Cancer.

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine

M. Mollenhauer, I. Herr, U. Haberkorn, 2014, Oncotarget.

Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.

M. Volm, J. Mattern, E. Pommerenke, 1991, Anticancer Research.

Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts

R. Herrmann, M. Volm, J. Mattern, 1985, Medical oncology and tumor pharmacotherapy.

Overexpression of P-glycoprotein in rat hepatocellular carcinomas induced with N-nitrosomorpholine.

M. Volm, T. Efferth, H. Zerban, 1990, Carcinogenesis.

Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib

I. Herr, Yan Zhang, L. Liu, 2014, Cell Death and Disease.

Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy.

M. Volm, M. Kaufmann, J. Mattern, 1979, European journal of cancer.

Association of resistance‐related protein expression with poor vascularization and low levels of oxygen in human rectal cancer

C Herfarth, M. Volm, C. Herfarth, 1996, International journal of cancer.

Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma.

M. Volm, E. W. Hahn, J. Mattern, 1988, Cancer research.

[Selective tumour chemotherapy using oncobiograms (author's transl)].

M. Volm, M. Kaufmann, K. Goerttler, 1974, Deutsche medizinische Wochenschrift.

Expression profile of proteins involved in the xenotransplantability of non-small cell lung cancers into athymic nude mice.

M. Volm, T. Efferth, J. Mattern, 2002, International journal of oncology.

Different growth rates of lung tumours in man and their xenografts in nude mice.

M. Volm, H. Toomes, J. Mattern, 1980, European journal of cancer.

CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients

I. Herr, M. Volm, J. Mattern, 2009, International journal of cancer.

Expression of drug resistance gene products during progression of lung carcinomas.

M. Volm, J. Mattern, R. Koomägi, 2002, Oncology reports.

Protein expression profiles indicative for drug resistance of non-small cell lung cancer

M. Volm, T. Efferth, J. Mattern, 2002, British Journal of Cancer.

Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiation in vivo.

M. Volm, T. Efferth, J. Mattern, 1991, Radiation research.

Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs

M. Volm, T. Efferth, F. Zintl, 2008, Clinical Cancer Research.

Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors

H. Friess, H. Dienemann, P. Altevogt, 2007, Cancer biology & therapy.

Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation

I. Herr, J. Werner, P. Schemmer, 2013, International journal of cancer.

Occurrence of a multidrug-resistant phenotype in human lung xenografts.

M. Volm, J. Mattern, M. Bak, 1987, British Journal of Cancer.

Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue†

J. Schneider, M. Volm, T. Efferth, 1992 .

Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.

M. Volm, E. W. Hahn, J. Mattern, 1988, British Journal of Cancer.

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

T. Giese, I. Herr, N. Giese, 2013, Cell Death and Disease.

Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells

I. Herr, T. Wenger, K. Debatin, 2003, British Journal of Cancer.

Expression of resistance factors (P‐glycoprotein, glutathione S‐transferase‐π, and topoisomerase II) and their interrelationship to proto‐oncogene products in renal cell carcinomas

M. Volm, T. Efferth, J. Mattern, 1993, Cancer.

Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.

M. Volm, J. Mattern, R. Koomägi, 1996, British Journal of Cancer.

Sensitivity tests of tumors to cytostatic agents

M. Volm, M. Kaufmann, J. Mattern, 2004, Zeitschrift für Krebsforschung und Klinische Onkologie.

Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.

M. Volm, J. Mattern, R. Koomagi, 1999, Oncology reports.

DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma.

M. Volm, E. W. Hahn, J. Mattern, 1988, Cytometry.

Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival. A five-year follow up study.

M. Volm, J. Mattern, T. Müller, 1988, Anticancer research.

Biological characterization of subgroups of squamous cell lung carcinomas.

M. Volm, J. Mattern, R. Koomägi, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Up-regulation of resistance-related proteins in human lung tumors with poor vascularization.

M. Volm, J. Mattern, R. Koomägi, 1995, Carcinogenesis.

Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer.

M. Volm, J. Mattern, C. Manegold, 1996, Cancer letters.

Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins.

M. Volm, J. Mattern, M. Bak, 1988, Arzneimittel-Forschung.

Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.

M. Volm, J. Mattern, B. Samsel, 1991, British Journal of Cancer.

[Individual chemotherapy of solid tumors].

M. Volm, J. Mattern, 1976, Die Medizinische Welt.

Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density.

M. Volm, J. Mattern, R. Koomägi, 1997, Anticancer research.

Resistance mechanisms in murine tumors with acquired multidrug resistance.

M. Volm, T. Efferth, J. Mattern, 1992, Arzneimittel-Forschung.

Vascular liver tumors induced in Mastomys (Praomys) natalensis by single or twofold administration of dimethylnitrosamine.

M. Volm, J. Mattern, P. Bannasch, 1979, Journal of the National Cancer Institute.

Determination of trace elements in peripheral lymphocytes from tumor-bearing rats

M. Volm, J. Mattern, K. Wayss, 1979, Experientia.

Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas

M. Volm, M. Kaufmann, J. Mattern, 1996, Clinical & Experimental Metastasis.

Effects of single doses of irradiation on the expression of resistance-related proteins in murine NIH 3T3 and human lung carcinoma cells.

M. Volm, J. Mattern, G. Stammler, 1995, Carcinogenesis.

Lung Xenografts as a Predictive Screen for Antineoplastic Agents

M. Volm, J. Mattern, K. Wayss, 1988 .

Growth of human bronchial carcinomas in nude mice.

M. Volm, J. Šonka, J. Mattern, 1985, British Journal of Cancer.

Sulforaphane targets pancreatic tumour-initiating cells by NF-κB-induced antiapoptotic signalling

P. Altevogt, A. Kolb, M. Büchler, 2008, Gut.

Dietary polyphenol quercetin targets pancreatic cancer stem cells.

M. Büchler, I. Herr, Wei Zhou, 2010, International journal of oncology.

Prognostic value of p16INK4A expression in lung adenocarcinoma.

M. Volm, J. Mattern, R. Koomägi, 1998, Anticancer research.

Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits.

M. Volm, J. Mattern, 1992, Carcinogenesis.

Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.

B. Lathan, M. Volm, T. Efferth, 1988, Anticancer research.

O6‐methylguanine‐DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts

M. Volm, B. Kaina, J. Mattern, 1998, International journal of cancer.

Short Communication Prognostic Value of Basic Fibroblast Growth Factor and Its Receptor (FGFR-1) in Patients with Non-small Cell Lung Carcinomas

M. Volm, J. Mattern, G. Stammler, 1997 .

Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins.

M. Volm, T. Efferth, J. Mattern, 1988, Anticancer research.

Resistance mechanisms in human lung cancer.

M. Volm, J. Mattern, 1995, Invasion & metastasis.

Messenger RNA expression of resistance factors in human tumor cell lines after single exposure to radiation.

M. Volm, J. Mattern, G. Stammler, 1996, Journal of experimental therapeutics & oncology.

Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil.

M. Volm, T. Efferth, J. Mattern, 1991, Chemotherapy.

High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue.

J. Schneider, M. Volm, T. Efferth, 1993, European journal of cancer.

Prediction of drug resistance in human tumors using immunohistochemical techniques.

M. Volm, J. Mattern, 1992, Anticancer research.

Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.

M. Volm, T. Efferth, J. Mattern, 1991, Anticancer Research.

Detection of induced tumour-resistance to cyclophosphamide by the in vitro short term test

M. Volm, J. Mattern, K. Wayss, 1977, Archiv für Gynäkologie.

Clinical correlates of in vitro effect of adriamycin on advanced lung carcinoma

M. Volm, M. Kaufmann, J. Mattern, 1976, Klinische Wochenschrift.

Non-existence of tissue specific growth inhibitors in the liver-supernatant ("hepatic chalone").

M. Volm, J. Mattern, K. Wayss, 1973, Experimentelle Pathologie.

Elimination by the carcinogen diethylnitrosamine of non-specific inhibitory factors in the regenerating liver.

M. Volm, J. Mattern, K. Wayss, 1973, Experimentelle Pathologie.

[Studies on the solid Walker-carcinosarcoma 256 in the rat during administration of cytostatics].

M. Volm, J. Mattern, K. Wayss, 1972, Arzneimittel-Forschung.

Detection of induced resistance to cytosine-arabinoside with a short-term test.

M. Volm, J. Mattern, E. Maas, 1980, European journal of cancer.

Predicting chemosensitivity of tumors

M. Volm, J. Mattern, K. Wayss, 2005, Breast Cancer Research and Treatment.

Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma.

D. Wallwiener, M. Volm, M. Kaufmann, 1997, Anticancer Research.

Xenotransplantability of human squamous cell lung cancer in nude mice is not affected by angiogenic factors.

M. Volm, J. Mattern, R. Koomägi, 1999, Anticancer research.

Maintenance of morphology and tumour marker production in human epidermoid lung carcinoma xenografts.

M. Volm, J. Mattern, M. Bak, 1987, In vivo.

Development of drug resistance in a human epidermoid lung carcinoma xenograft line.

M. Volm, J. Mattern, M. Bak, 1988, British Journal of Cancer.

Effect of five antineoplastic agents on tumor xenografts with different growth rates.

M. Volm, J. Mattern, K. Wayss, 1984, Journal of the National Cancer Institute.

Predictive value of statin, a g‐associated cell cycle protein, in childhood acute lymphoblastic leukemia

J. Mattern, A. Sauerbrey, S. Hecker, 1995, International journal of cancer.

Angiostatin expression in non-small cell lung cancer.

M. Volm, J. Mattern, R. Koomägi, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Imbalance of cell proliferation and apoptosis during progression of lung carcinomas.

M. Volm, J. Mattern, 2004, Anticancer research.

Vascular endothelial growth factor and basic fibroblast growth factor in primary lung carcinomas and the incidence of metastases.

M. Volm, J. Mattern, R. Koomagi, 1996, International journal of oncology.

Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas

M. Volm, J. Mattern, Reet Koomugi, 1998, Clinical & Experimental Metastasis.

[Resistance testing and chemotherapy results of bronchial tumours (author's transl)].

M. Volm, J. Mattern, K. Wayss, 1978, Deutsche Medizinische Wochenschrift.

Detection of Multiple Resistance Mechanisms in Untreated Human Lung Cancer

M. Volm, J. Mattern, 1993 .

Use of gene transfer and a novel cosmid rescue strategy to isolate transforming sequences.

G. Schütz, J. Mattern, G. Brady, 1985, The EMBO journal.

Microvessel density and vascular endothelial growth factor expression in human tumors of different localization.

M. Volm, J. Mattern, 1996, Oncology reports.

Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P‐glycoprotein 170, and glutathione S‐transf erase‐π in human lung tumors

M. Volm, J. Mattern, B. Samsel, 1992, Cancer.

Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas.

M. Volm, J. Mattern, 1992, Anticancer research.

Significance of proliferation for the growth of xenografted human tumours in nude mice.

M. Volm, J. Mattern, K. Wayss, 1981 .

[Possibilities and limits of pre-therapeutic neoplasm sensitivity cytostatics tests under short-term conditions].

M. Volm, M. Kaufmann, J. Mattern, 1975, Schweizerische medizinische Wochenschrift.

Clinical prognostic relevance of growth of human adenocarcinomas of the lung in nude mice.

M. Volm, J. Mattern, 1987, Anticancer Research.

Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance.

M. Volm, J. Mattern, R. Koomägi, 1997, Anti-cancer drugs.

Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.

M. Büchler, I. Herr, M. Zöller, 2010, Cancer research.

Therapy of solid Walker carcinosarcoma 256 with bleomycin after synchronization with hydroxyurea

M. Volm, N. Weber, J. Mattern, 2004, Cancer Chemotherapy and Pharmacology.

Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice.

M. Volm, J. Mattern, Mihály Bak, 1990, Anticancer research.

Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs

M. Volm, T. Efferth, F. Zintl, 2008, Clinical Cancer Research.

Effect of synchronization on chemotherapy of solid transplanted tumours.

M. Volm, J. Mattern, K. Wayss, 1977, European journal of cancer.

The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results.

M. Volm, J. Mattern, K. Wayss, 1974, Archiv fur Geschwulstforschung.

N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

J. Schneider, M. Kaufmann, J. Mattern, 1989, British Journal of Cancer.

Acquired drug resistance in human lung carcinoma xenografts.

M. Volm, T. Efferth, J. Mattern, 1989, Arzneimittel-Forschung.